Bellmunt risk score enables survival prediction in men with metastatic castration resistant prostate cancer (mCRPC) undergoing PSMA-targeted radioligand therapy (LUMEN)
Bellmunt 风险评分能够预测接受 PSMA 靶向放射性配体治疗的转移性去势抵抗性前列腺癌 (mCRPC) 患者的生存情况 (LUMEN)
期刊:European Journal of Nuclear Medicine and Molecular Imaging
影响因子:7.6
doi:10.1007/s00259-025-07492-9
Büttner, Thomas; Marinova, Milka; Gaertner, Florian C; Kreppel, Barbara; Fritsche, Leander; Immanuel, Christian; Geraths, Gerd; Kürpig, Stefan; Küppers, Jim; Schmidt-Wolf, Ingo G H; Essler, Markus; Ritter, Manuel; Krausewitz, Philipp
